FDG-PET Response Predicts Survival in Anal Cancer
Author Information
Author(s): Day F L, Link E, Ngan S, Leong T, Moodie K, Lynch C, Michael M, Winton E de, Hogg A, Hicks R J, Heriot A
Primary Institution: Peter MacCallum Cancer Centre
Hypothesis
The study aimed to investigate the correlation between FDG-PET metabolic response to chemoradiotherapy and clinical outcomes in anal cancer.
Conclusion
FDG-PET metabolic response to chemoradiotherapy in anal cancer is significantly associated with progression-free survival and overall survival.
Supporting Evidence
- 79% of patients had a complete metabolic response at all sites of disease.
- 2-year progression-free survival was 95% for patients with a complete metabolic response.
- 5-year overall survival was 88% in patients with a complete metabolic response.
Takeaway
This study found that how well anal cancer responds to a special scan after treatment can help doctors predict how long patients will live.
Methodology
Patients with anal SCC underwent FDG-PET scans before and after chemoradiotherapy, and survival outcomes were analyzed using Kaplan–Meier methods.
Potential Biases
There may be selection bias in the patients who underwent both pre- and post-therapy FDG-PET scans.
Limitations
The study is retrospective and conducted at a single institution, which may limit the generalizability of the findings.
Participant Demographics
The median age of participants was 56 years, with a mix of male and female patients.
Statistical Information
P-Value
P<0.0001
Confidence Interval
95% CI: 1.5–11.5 for PFS; 95% CI: 2.1–21.6 for OS
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website